SmartPractice Allergen Bank, L.L.C.
$1.6M 4 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Endologix LLC
Endologix LLC reported $1,617,964.74 across General Payments, Research, and Ownership to 4,167 physicians and teaching hospitals across 4,441 transactions.
- $1.6M Above-median payer
- All-tracks total
- 4,441 Top quartile volume
- Transactions
- 4,167 Top quartile reach
- Recipients
- −$27.7K
- General Payments vs PY2023
Endologix LLC reported $1,617,964.74 across all CMS Open Payments tracks (General + Research + Ownership) to 4,167 physicians and teaching hospitals in Program Year 2024 - ranking #501 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $725,401.85, averaging $388.28 per recipient.
How Endologix LLC's $1.6M all-tracks total breaks down
Endologix LLC's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
43/100
Total payments
F
25/100
Transaction volume
F
42/100
Physician reach
F
42/100
Payment type diversity
D
63/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer endologix-llc Endologix LLC
$1.6M · #501/1,925 · 0.0% industry · PY2024
- TOT $1.6M
- RANK #501
- SHARE 0.0%
- TXN 4,441
- RCP 4,167
- CAT 5
- GEN $725.4K
- ΔGEN −$27.7K
- TOP1 4.1%
- PY 2024
Volume peers
Nearest volume peer: SmartPractice Allergen Bank, L.L.C. ($1.6M)
Endologix LLC sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Endologix LLC's CMS-reported General Payments decreased by $27.7K (−3.7%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: ENDOLOGIX LLCPY2023: ENDOLOGIX LLCPY2024: Endologix LLC. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $753,086.13
- PY2024
- $725,401.85
What the Data Shows for Endologix LLC
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For Endologix LLC, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
3,824 transactions worth $432.2K make "Food and Beverage" the top general-payment category in the 5-category breakdown below, 59.6% of General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
"Food and Beverage" leads Endologix LLC's 5-category general-payment breakdown at $432.2K, 59.6% of the reported total.
Endologix LLC reports 5 general-payment categories - the top three are Food and Beverage (59.6%), Consulting Fee (34.2%), and Travel and Lodging (3.8%). The remaining 2 categories make up 2.4% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Endologix LLC divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Food and Beverage | $432.2K | 3,824 | 59.6% |
| Consulting Fee | $248.4K | 244 | 34.2% |
| Travel and Lodging | $27.4K | 85 | 3.8% |
| Grant | $15.0K | 1 | 2.1% |
| Education | $2.4K | 13 | 0.3% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $104,013.51 (14.3%) of $725,401.85 in this company's General Payments records across 1,527 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Endologix LLC
The five named recipients with the highest reported General Payments from this company
- 1
Anthony C. Feghali
$29,539.12 across 73 reported transactions
- 2
Sonya Noor
$21,352.90 across 33 reported transactions
- 3
Vincent Digiovanni
$18,585.81 across 39 reported transactions
- 4
John Park
$17,487.12 across 50 reported transactions
- 5
Mark Conrad
$17,048.56 across 41 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Endologix LLC ranks #501 of 1,925 by total payments (top 26% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,713 of 1,838 by HHI (bottom 7% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- LEO Pharma Inc. : $3.1M total payments, HHI 88
- Medinc of Texas : $86.5K total payments, HHI 87
- Vertical Pharmaceuticals, LLC : $60.9K total payments, HHI 86
- Sight Sciences, Inc. : $1.0M total payments, HHI 85
- Astellas Pharma US Inc : $10.6M total payments, HHI 85
- Centrix Inc : $17.9K total payments, HHI 84
- Endologix LLC (this company) : $725.4K total payments, HHI 84
- Novartis Pharmaceuticals Corporation : $19.7M total payments, HHI 84
- Seapearl East, Inc : $93.9K total payments, HHI 83
- Spinal Elements, Inc. : $50.6K total payments, HHI 83
- Tris Pharma Inc : $742.6K total payments, HHI 83
- Aquestive Therapeutics, Inc. : $5.5K total payments, HHI 81
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Endologix LLC's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Endologix LLC.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Endologix LLC.
Showing 6 of 1,924 companies with CMS-reported payment data.
Scpharmaceuticals Inc.
$1.6M 13,366 recipients
Compare payment profiles
Terumo Medical Corporation
$1.6M 6,609 recipients
Compare payment profiles
Menarini Silicon Biosystems, Inc.
$1.6M 490 recipients
Compare payment profiles
Neuropace, Inc.
$1.6M 1,828 recipients
Compare payment profiles
Zavation Medical Products, LLC
$1.6M 560 recipients
Compare payment profiles
Put this to use
Endologix LLC ranks #501 of 1,925 by all-tracks total payments, led by "Food and Beverage".
- See where Endologix LLC sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Food and Beverage" spend across every manufacturer, not just Endologix LLC. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.